Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the ...

DBS Bank dominates LinkedIn's 2025 Top Companies in Singapore list for the third time in a row, topping the best companies for career growth in the country.

This process formed a thin film with a lamellar (layered) structure. The film was then calcinated in air at 170 °C for 4 hours, resulting in the removal of the PEO and PPO blocks. This process ...

*Ministry of Corporate Affairs, 2019, Company/LLP Data, (Government of India administrative body to govern and regulate corporate affairs through the Companies Act ...

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...

Merck has recently achieved a significant milestone with the European Commission's approval of its pneumococcal vaccine CAPVAXIVE®, boosting its portfolio in the vaccines market. Despite this ...

40% of Merck & Co., Inc.'s revenues are driven by ... a Pharma can submit its drug for regulatory review and commercial approval, a process that takes ~10 months). The company is certainly not ...

Merck (MRK) has signed a licensing agreement for a heart disease drug developed by a Chinese company in a deal worth up to $2 billion, the latest in a series of cross-border deals between Western ...

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor. In return for the ex-China rights to the drug, dubbed HRS-5346, Merck has ...

non-invasive testing solutions, today provided shareholders with a status update on the FDA clearance process for its Intelligent Fingerprint Drug Screening System, which remains on track for ...

(Reuters) -Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the latest in a series of deals U.S. drugmakers have ...